Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
Clinical trial NCT00975130 · COMPLETED
Trial details
- NCT number
- NCT00975130
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2009-09-01
- Primary completion
- 2011-08-01
- Enrollment
- 3366
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.